The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor agonist , alongside Retatrutide , a triple GIP/GLP-1/GCG receptor agonist , https://sparxsocial.com/story478166/retatrutide-and-nmn-a-triple-threat-system-to-general-wellness